These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 1496666)

  • 1. Lipid disorders in renal transplant recipients.
    Kainuma O; Asano T; Ochiai T; Isono K
    Transplant Proc; 1992 Aug; 24(4):1585-7. PubMed ID: 1496666
    [No Abstract]   [Full Text] [Related]  

  • 2. Prospective monitoring of lipid profiles in children receiving pravastatin preemptively after renal transplantation.
    Butani L
    Pediatr Transplant; 2005 Dec; 9(6):746-53. PubMed ID: 16269046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does pravastatin safely and effectively improve lipid profiles in children who have received a kidney transplant?
    Silverstein DM
    Nat Clin Pract Nephrol; 2006 Jun; 2(6):306-7. PubMed ID: 16932448
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of pravastatin on renal transplant recipients treated with cyclosporine--4-year follow-up.
    Yoshimura N; Ohmori Y; Tsuji T; Oka T
    Transplant Proc; 1994 Oct; 26(5):2632-3. PubMed ID: 7940820
    [No Abstract]   [Full Text] [Related]  

  • 5. Tacrolimus-induced elevation in plasma triglyceride concentrations after administration to renal transplant patients is partially due to a decrease in lipoprotein lipase activity and plasma concentrations.
    Tory R; Sachs-Barrable K; Goshko CB; Hill JS; Wasan KM
    Transplantation; 2009 Jul; 88(1):62-8. PubMed ID: 19584682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of renal transplantation with a minimal steroid regime on uraemic hypertriglyceridaemia.
    Turgan C; Russell GI; Baker F; Walls J
    Q J Med; 1984; 53(210):271-7. PubMed ID: 6379726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of fluvastatin on hyperlipidemia after renal transplantation.
    Tokumoto T; Tanabe K; Ishida H; Shimmura H; Ishikawa N; Goya N; Akiba T; Toma H
    Transplant Proc; 2004 Sep; 36(7):2141-4. PubMed ID: 15518777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of dyslipidemia in renal disease and transplantation.
    Zolezzi M
    Saudi J Kidney Dis Transpl; 2006 Jun; 17(2):129-36. PubMed ID: 16903617
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparative effects of two HMG-CoA reductase inhibitors (lovastatin and pravastatin) on serum lipids and lipoproteins.
    Richter WO; Jacob BG; Schwandt P
    Int J Tissue React; 1991; 13(2):107-10. PubMed ID: 1955291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abnormal lipoprotein (a) and lipid profiles in renal allograft recipients: effects of treatment with pravastatin.
    Lye WC; Hughes K; Leong SO; Tan CC; Lee EJ
    Transplant Proc; 1995 Feb; 27(1):977-8. PubMed ID: 7879252
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of pravastatin and lovastatin in renal transplant patients receiving cyclosporine.
    Kliem V; Wanner C; Eisenhauer T; Olbricht CJ; Doll R; Boddaert M; O'Grady P; Krekler M; Mangold B; Christians U
    Transplant Proc; 1996 Dec; 28(6):3126-8. PubMed ID: 8962211
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison of the efficacy and safety of pravastatin and simvastatin in heart transplantation.
    Vivekananthan K; Mehra MR; Uber PA; DeGruiter H; Lavie CJ; Milani RV
    J Assoc Physicians India; 2002 May; 50(5):682-4. PubMed ID: 12186124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with ezetimibe in kidney transplant recipients with uncontrolled dyslipidemia.
    López V; Gutiérrez C; Gutiérrez E; Sola E; Cabello M; Burgos D; González Molina M
    Transplant Proc; 2008 Nov; 40(9):2925-6. PubMed ID: 19010149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ezetimibe reduces low-density lipoprotein cholesterol (LDL-C) in renal transplant patients resistant to HMG-CoA reductase inhibitors.
    Chuang P; Langone AJ
    Am J Ther; 2007; 14(5):438-41. PubMed ID: 17890931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Statins (HMG-CoA reductase inhibitors), cholesterol and stroke].
    Marta-Moreno J; Echeandia C; Oliveros-Cid A; Figuerola A; Mola S
    Rev Neurol; 1998 Nov; 27(159):827-30. PubMed ID: 9859160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of statin therapy in patients switched from cyclosporine a to sirolimus after cardiac transplantation.
    Aliabadi AZ; Mahr S; Dunkler D; Grömmer M; Zimpfer D; Wolner E; Grimm M; Zuckermann AO
    Transplantation; 2008 Dec; 86(12):1771-6. PubMed ID: 19104420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Disorders of lipid metabolism and renal failure--what is cause, what is sequelae?].
    DerFler K
    Wien Klin Wochenschr; 1996; 108(14):417-9. PubMed ID: 8928513
    [No Abstract]   [Full Text] [Related]  

  • 18. The inhibitory effects of pravastatin on natural killer cell activity in vivo and on cytotoxic T lymphocyte activity in vitro.
    Katznelson S; Wang XM; Chia D; Ozawa M; Zhong HP; Hirata M; Terasaki PI; Kobashigawa JA
    J Heart Lung Transplant; 1998 Apr; 17(4):335-40. PubMed ID: 9588577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal function and lipid metabolism in pregnant renal transplant recipients.
    Czajkowski K; Wójcicka-Bentyn J; Sieńko J; Grymowicz M; Smolarczyk R; Malinowska-Polubiec A; Romejko E
    Eur J Obstet Gynecol Reprod Biol; 2004 Jun; 114(2):155-61. PubMed ID: 15140508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pravastatin therapy is associated with reduction in coronary allograft vasculopathy in pediatric heart transplantation.
    Mahle WT; Vincent RN; Berg AM; Kanter KR
    J Heart Lung Transplant; 2005 Jan; 24(1):63-6. PubMed ID: 15653381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.